Reuters -- Molecular Insight Pharmaceuticals Inc (MIPI.O) said data from a mid-stage trial of its cancer drug, Onalta, showed the drug improved symptoms associated with metastatic carcinoid tumors, sending its shares up 58 percent in post-market trade.
